Neuropace/$NPCE
NeuroPace shares are trading lower following an investigation into potential securities fraud.
1 hour ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neuropace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Ticker
$NPCE
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
195
ISIN
US6412881053
Website
Neuropace Metrics
BasicAdvanced
$430M
-
-$0.83
2.05
-
Price and volume
Market cap
$430M
Beta
2.05
52-week high
$18.98
52-week low
$5.45
Average daily volume
357K
Financial strength
Current ratio
6.628
Quick ratio
5.555
Long term debt to equity
293.498
Total debt to equity
301.422
Interest coverage (TTM)
-2.22%
Management effectiveness
Return on assets (TTM)
-11.52%
Return on equity (TTM)
-128.49%
Valuation
Price to revenue (TTM)
4.654
Price to book
17.69
Price to tangible book (TTM)
17.69
Price to free cash flow (TTM)
-21.625
Growth
Revenue change (TTM)
22.05%
Earnings per share change (TTM)
-30.08%
3-year revenue growth (CAGR)
22.97%
3-year earnings per share growth (CAGR)
-21.48%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Neuropace News
AllArticlesVideos
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc. - Contact Levi & Korsinsky
Accesswire·1 hour ago
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud
Accesswire·23 hours ago
Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation
Accesswire·24 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neuropace stock?
Neuropace (NPCE) has a market cap of $430M as of May 30, 2025.
What is the P/E ratio for Neuropace stock?
The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of May 30, 2025.
Does Neuropace stock pay dividends?
No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Neuropace dividend payment date?
Neuropace (NPCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuropace?
Neuropace (NPCE) has a beta rating of 2.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.